TUCSON, Ariz., Feb. 27, 2017  -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM)("HTG"), a provider of instruments, reagents and services for molecular profiling applications announced that its new direct-target sequencing chemistry will be available in the company’s VERI/O laboratory as a service offering beginning in the first quarter of 2017.  The new chemistry is designed for direct sequencing of specified DNA and, in the future, RNA targets with the same high sensitivity and specificity as the company’s current HTG EdgeSeq chemistry applications. The initial panel planned for the VERI/O laboratory will detect common mutations in the EGFR, KRAS and BRAF genes for retrospective research studies especially from small and difficult samples, such as formalin-fixed, paraffin-embedded (FFPE) tissue.

PARSIPPANY, N.J., Jan. 3, 2017 -- Interpace Diagnostics Corp. (NASDAQ: IDXG), a company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risks of cancer, announced today that the Company has entered in to an Agreement with the Blue Cross Blue Shield (BCBS) Association's Center for Clinical Effectiveness "Evidence Street", a program that, while not making coverage decisions, provides the Company with the opportunity to provide available evidence for its molecular Thyroid and Pancreas tests, to support further coverage determinations among Blue Cross Blue Shield and other health plans. Blue Cross Blue Shield's 36 independent plans and Companies account for approximately 106 million covered lives in the U.S. 

 

As part of the Agreement, Interpace will work with Evidence Street to develop the optimal ways for the Company to secure and preserve ongoing coverage for not only its currently marketed products but also for those tests in the pipeline being launched in the near future. All of Interpace's currently marketed products are covered regionally by Medicare and numerous commercial plans, including certain BCBS plans. 

Patient Registry of ThyGenX and ThyramiR Designed to Further Validate Combination Test's Clinical Utility

 

PARSIPPANY, N.J., Dec. 13, 2016 -- Interpace Diagnostics Corp. (NASDAQ: IDXG), a company that provides clinically useful molecular diagnostic tests and pathology services, announced today that the Company has launched a multi-site study to provide further evidence of the Clinical Utility of the ThyGenX/ThyramiR tests in accurately identifying malignancy or benign status in indeterminate thyroid nodules.  The primary objective of the study is to demonstrate the real world clinical utility of the test, i.e. the degree to which the tests impact physician decision-making and positively affect patient outcomes.  To date, the Company has performed the combination assay on over 5,000 patients on behalf of over 200 physicians and hospitals nationwide. 

Aetna Issues Favorable Coverage Policy for ThyraMir™ for Indeterminate Thyroid Nodules

 

PARSIPPANY, N.J., Dec. 8, 2016  -- Interpace Diagnostics Corp. (NASDAQ: IDXG), a company that provides clinically useful molecular diagnostic tests and pathology services, announced today that Aetna, the third largest health plan in the United States, has agreed to cover Interpace's ThyraMir™ test for all of Aetna's 46 million members nationwide, with coverage effective immediately.  Interpace's ThyGenX™ and ThyraMir thyroid assays are now covered for approximately 200 million patients nationwide, including through Medicare, National, and Regional health plans.